September 27, 2024
FDA Considers Restricting PD-1 Drugs in Stomach and Esophageal Cancers Based on PD-L1 Expression
PD-1 drugs, stomach cancer, esophageal cancer, PD-L1 expression, FDA restrictions, pembrolizumab, nivolumab, tislelizumab
AbbVie’s Tavapadon Shows Promising Results in Phase III Trial for Parkinson’s Disease
AbbVie, Tavapadon, Parkinson’s Disease, Phase III Trial, TEMPO-1, Cerevel Therapeutics
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval